QUOTE AND NEWS
Business Wire  Jan 28  Comment 
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced initiation of a Phase 1 clinical trial of IMO-3100, an antagonist of Toll-like Receptor (TLR) 7 and TLR9. “As an antagonist of TLR7 and TLR9, IMO-3100 has a novel mechanism of action and
Business Wire  Jan 26  Comment 
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the election of Malcolm MacCoss, Ph.D., FRSC, to the Company's Board of Directors as a class II director. Dr. MacCoss has nearly 30 years of drug discovery and development experience with
StreetInsider.com  Jan 19  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Idera+Pharma+%28IDRA%29+to+Receive+%244.3M+from+Merck+%28MRK%29+for+Milestone+Achievement/5254960.html for the full story.
Business Wire  Jan 19  Comment 
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt, Germany. The milestone was achieved upon initiation of a Phase 2 trial
Business Wire  Dec 21  Comment 
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced positive interim results from a Phase 1 clinical trial of IMO-2125 in patients with chronic hepatitis C virus infection (HCV). IMO-2125 is an agonist of Toll-like Receptor 9 that Idera
Business Wire  Dec 4  Comment 
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like Receptors (TLR), announced today the appointment of Rahul Jasuja, Ph.D., as Vice
Business Wire  Nov 25  Comment 
Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that Novartis will terminate its research collaboration agreement with the Company, effective as of February 21, 2010. “We appreciate the commitment Novartis scientists provided throughout
StreetInsider.com  Nov 5  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Idera+Pharma+%28IDRA%29+Posts+Break-Even+Q3+EPS%2C+Down+8c+from+Q308/5077954.html for the full story.
StreetInsider.com  Nov 3  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Idera+Pharma+%28IDRA%29+Presents+IMO-2125+Preclinical+Data/5068620.html for the full story.
StreetInsider.com  Oct 26  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Idera+Pharma+%28IDRA%29+Announces+TLR+Patent+Issuance/5043426.html for the full story.



Thank you for your suggestion


 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki